Category - Developments

Developments

Profound Medical’s new president makes open market purchase of company shares

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) president, Richard Fabian, acquired a total of 10,000 shares of Profound on the open market today at a cost of $59,800 (U.S.). In a sign of...

September 17, 2026

Developments

Xenetic and Santersus enter into definitive share exchange agreement

Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected...

September 17, 2026

Developments

BioPorto initiates patient enrollment in adult urine NGAL validation study

BioPorto (CPH: BIOPOR) has announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to...

September 17, 2026

Developments

Firefly’s Evoke platform selected for Radial’s AI-native brain medicine operating system

Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic collaboration with closely held Radial, operator of the U.S.’s largest network of brain medicine clinics, to pursue the integration of Firefly’s...

September 17, 2026

Developments

FDA grants Armata Breakthrough Therapy designation for AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate, for...

September 14, 2026

Developments

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced a clinical trial collaboration agreement with Merck (NYSE: MRK) to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda...

September 14, 2026

Developments

Q32 Bio names Drs. José Trevejo as CMO and Ellie Hershberger as CDO

Q32 Bio (NASDAQ: QTTB) has announced the appointment of José Trevejo, MD, PhD, as chief medical officer (CMO) and Ellie Hershberger, PharmD, as chief development officer (CDO). Prior to joining Q32 Bio, Dr. Trevejo...

September 14, 2026

Developments

Eloxx announces first patients dosed in study of exaluren in NMAS

Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). According to...

September 11, 2026

Developments

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of the first patients with alcohol use disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the company’s proprietary psychedelic-based...

September 11, 2026

Developments

IMUNON enters CRADA with NCI to advance gene-based immunotherapy

IMUNON (NASDAQ: IMNN) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to support further clinical and non-clinical development of IMNN-001, the...

September 10, 2026

Category - Developments

Subscribe